What are the potential benefits and risks of using veterinary antiparasitic agents as adjuncts to conventional cancer therapies?

The potential benefits of using veterinary antiparasitic agents, such as Fenbendazole For Humans, as adjuncts to conventional cancer therapies include their ability to target cancer cell metabolism and microtubule dynamics, potentially enhancing the efficacy of existing treatments. Additionally, these agents are often inexpensive and widely available. However, the risks involve the lack of comprehensive data on their safety and efficacy in humans, potential adverse effects such as liver injury, and the possibility of unforeseen interactions with standard cancer treatments. Therefore, thorough clinical investigations are essential before these agents can be recommended as adjunctive cancer therapies.